GALT compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

GALTGalectin Therapeutics Inc

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

GALTGalectin Therapeutics Inc

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

GALT1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±26.6%▼−2.55%×0.09

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedGALT realized, solidLLY realized, hatchedOne scale, both sides: full bar = 27%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

GALTGalectin Therapeutics Inc

3.16▲+5.77%· post 3.16

Mkt cap$316.7MRevenue—Revenue—

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

GALTGalectin Therapeutics Inc

LLYELI Lilly & Co

3.16▲+5.77%post 3.16

Price

1,360.90▼−0.28%post 1,358.90

$316.7M

Mkt cap

$1.2T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

GALT3.16▲+5.77%vsLLY1,360.90▼−0.28%ClosedNov 6 '26